BCR-ABL PCR testing in chronic myelogenous leukemia: Molecular diagnosis for targeted cancer therapy and monitoring

Martin H. Luu, Richard Press

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.

Original languageEnglish (US)
Pages (from-to)749-762
Number of pages14
JournalExpert Review of Molecular Diagnostics
Volume13
Issue number7
DOIs
StatePublished - 2013

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase Chain Reaction
Protein-Tyrosine Kinases
Neoplasms
Residual Neoplasm
Reverse Transcription
Decision Making
Chronic Disease
Therapeutics

Keywords

  • RQ-PCR

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

@article{1c8ebb063a10441c9096d373b288b163,
title = "BCR-ABL PCR testing in chronic myelogenous leukemia: Molecular diagnosis for targeted cancer therapy and monitoring",
abstract = "The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.",
keywords = "RQ-PCR",
author = "Luu, {Martin H.} and Richard Press",
year = "2013",
doi = "10.1586/14737159.2013.835573",
language = "English (US)",
volume = "13",
pages = "749--762",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - BCR-ABL PCR testing in chronic myelogenous leukemia

T2 - Molecular diagnosis for targeted cancer therapy and monitoring

AU - Luu, Martin H.

AU - Press, Richard

PY - 2013

Y1 - 2013

N2 - The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.

AB - The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.

KW - RQ-PCR

UR - http://www.scopus.com/inward/record.url?scp=84885606228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885606228&partnerID=8YFLogxK

U2 - 10.1586/14737159.2013.835573

DO - 10.1586/14737159.2013.835573

M3 - Article

C2 - 24063401

AN - SCOPUS:84885606228

VL - 13

SP - 749

EP - 762

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 7

ER -